Abstract
Purpose
To report clinical (visual and refractive), spectacle independence, patient-reported outcomes following bilateral sequential implantation of a non-diffractive extended-vision intraocular lens (IOL): AcrySof IQ Vivity (DFT015 and DFTx15) in cataract surgery. This IOL provides continuous range of focus from distance to near, offering monofocal quality distance image and visual disturbances profile.
Methods
Retrospective unmasked nonrandomized case series. Patients who underwent phacoemulsification and bilateral sequential implantation of AcrySof IQ Vivity, targeting minimonovision (nondominant eye targeted for between −0.25D and −0.50D). Clinical post-operative outcome measures were assessed 1–2 months postoperatively - binocular uncorrected distance visual acuity (UDVA), binocular uncorrected intermediate visual acuity – 66 cm (UIVA), binocular uncorrected near visual acuity – 40 cm (UNVA), refraction, spherical equivalent (SE) and residual astigmatism (toric group). Spectacle independence and satisfaction systematic questionnaires (IOLSAT and Catquest-9SF) were performed. Visual disturbances were analyzed.
Results
181 patients were enrolled. 78 eyes were implanted with the DFTx15 (toric version). Binocular mean UDVA was −0.01 logMAR (± 0.05), binocular mean UIVA was 0.09 logMAR (± 0.08), binocular mean UNVA was 0.16 logMAR (± 0.12) and mean SE was −0.27D (± 0.36D). Mean residual astigmatism (toric group) was 0.3D (± 0.42D). Patient-reported outcomes for satisfaction and spectacle independence were excellent. Visual disturbances were rarely reported.
Conclusions
Implanting this IOL using minimonovision strategy provides excellent binocular UDVA and UIVA, and good UNVA. It provides high patient satisfaction, spectacle independence (demonstrated excellent performance in systematic evaluations) and minimizes unwanted visual effects. Controlled designs and longer follow-ups are needed to confirm these findings.
Get full access to this article
View all access options for this article.